Therapeutic impact of 18 F-FDG PET/CT for initial staging in patients with clinical stage I and IIA, HER2-positive, or triple-negative breast cancer.
Chloé FrançoisAudrey MailliezSebastian ChretienClémence LeguilletteAurore OudouxLuc CeugnartMaël BarthoulotOlivier CougnencAnaïs OlivierPublished in: Breast cancer research and treatment (2024)
Considering substantial therapeutic implications, our study suggests the usefulness of FDG-PET/CT for patients with stage IIA, HER2-positive, or Triple-Negative BC with tumor size > 2 cm (T2N0).
Keyphrases